Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Yoshiki ArakawaYoshitaka NaritaMotoo NaganeKazuhiko MishimaYasuhito TeruiHajime YonezawaKatsunori AsaiNoriko FukuharaKazuhiko SugiyamaNaoki ShinojimaArata AoiRyo NishikawaPublished in: Neuro-oncology advances (2023)
Tirabrutinib generally maintains KPS and QoL scores with some improvements in specific QoL items in patients with r/r PCNSL.